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Abstract
The relationship between dyslipidemia and type 2 diabetes mellitus (T2D) has been extensively reported, but the global
lipid profiles, especially in the East Asia population, associated with the development of T2D remain to be characterized.
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Liquid chromatography coupled to tandem mass spectrometry was applied to detect the global lipidome in the fasting
plasma of 293 Chinese individuals, including 114 T2D patients, 81 prediabetic subjects, and 98 individuals with normal
glucose tolerance (NGT). Both qualitative and quantitative analyses revealed a gradual change in plasma lipid features with
T2D patients exhibiting characteristics close to those of prediabetic individuals, whereas they differed significantly from
individuals with NGT. We constructed and validated a random forest classifier with 28 lipidomic features that effectively
discriminated T2D from NGT or prediabetes. Most of the selected features significantly correlated with diabetic clinical
indices. Hydroxybutyrylcarnitine was positively correlated with fasting plasma glucose, 2-hour postprandial glucose,
glycated hemoglobin, and insulin resistance index (HOMA-IR). Lysophosphatidylcholines such as lysophosphatidylcholine
(18:0), lysophosphatidylcholine (18:1), and lysophosphatidylcholine (18:2) were all negatively correlated with HOMA-IR. The
altered plasma lipidome in Chinese T2D and prediabetic subjects suggests that lipid features may play a role in the
pathogenesis of T2D and that such features may provide a basis for evaluating risk and monitoring disease development.
Keywords: lipidomics; type 2 diabetes; prediabetes; plasma
Background
Type 2 diabetes mellitus (T2D) is a progressive and complex dis-
ease that is tightly associated with heterogeneous metabolic
disorders, particularly in glucose and lipid metabolism [1]. The
prevalence of prediabetes, defined by blood glucose levels be-
tween normal and diabetic levels, is increasing rapidly world-
wide. Hence, characterization of abnormalities in glucose and
lipid metabolism at the prediabetic state is warranted. The high
prevalence of prediabetes and T2D is rapidly increasing in highly
populated countries like China. Using criteria defined by the
World Health Organization (WHO) and American Diabetes As-
sociation, 2 national epidemiological studies reported that the
prevalence of adult diabetes in Chinawas 9.7% in 2007 and 11.6%
in 2010, respectively, whereas the prevalence of adult predia-
betes ranged from 15.5% to 50.1% [2, 3].
As a strong association between T2D and dysregulation of
lipid metabolism is well established [1], metabolomics tech-
niques, especially lipidomics, represent powerful tools to glob-
ally survey metabolites associated with prediabetes and T2D.
Further, metabolomic analyses may provide insight into on-
going biochemical processes and identify biomarkers to pre-
dict disease risk. In a longitudinal study comprising 2422 nor-
moglycemic individuals followed for 12 years, plasma levels
of 3 branched-chain amino acids (BCAA; isoleucine, leucine,
valine) and 2 aromatic amino acids (tyrosine and phenylala-
nine) exhibited highly significant associations with the future
development of diabetes [4]. By comparing metabolomic pro-
files of obese versus lean humans, Newgard et al. have further
revealed a BCAA-related metabolite signature that correlates
with insulin resistance, and the concomitant specific in-
creases in C3 and C5 acyl-carnitine levels suggested increased
catabolism of BCAA [5]. Rat studies based on these findings
demonstrated that supplementation of a high-fat diet with
BCAA caused insulin resistance despite reduced food intake and
bodyweight [5]. Comparedwith lean subjects, obese nondiabetic
and T2D subjects exhibit increased levels of long-chain acyl-
carnitines, suggesting impairment of entry of fatty acids into
mitochondria [6]. Additionally, T2D adults of comparable body
mass index (BMI) exhibit increased levels of several short- and
medium-chain acyl-carnitines, suggesting that diabetic subjects
generally suffer from a complex oxidation defect [6]. The strong
association between prediabetes, T2D, and dysregulation of lipid
metabolism is further supported by the plasma profiling of 117
T2D, 64 prediabetes, and 170 normal glucose tolerant (NGT)
participants using targeted lipidomics [7]. This study revealed
that over 100 individual lipid species, including sphingolipids,
phospholipids, glycerolipids, ceramides, and cholesterol esters,
were tightly associated with T2D and prediabetes [7]. Addition-
ally, T2D risk classification models of potential value for clinical
use have been developed and evaluated by Meikle and cowork-
ers to stratify individuals with a fasting plasma glucose (FPG)
< 6.1 mmol/L using lipidomics profiles with or without non-
lipid risk factors [8]. Non-targeted lipidomics further repre-
sents a tool to discover metabolic regulatory networks and
thereby increases our understanding of lipid metabolism in
the pathophysiology of metabolic diseases including T2D [9].
Of note, it has been reported that East and South Asians de-
velop T2D at a lower mean BMI compared to the Western pop-
ulation [10], and Asians have more body fat and a higher ten-
dency to visceral adiposity for a given BMI than the West-
ern diabetes population [10]. Hence, characterizing the T2D
lipid profile in an Asian population (represented by Chinese)
could help fill the gaps in understanding these interethnic
differences.
The conventional data-dependent acquisition (DDA) mass
spectrometry (MS) mode has been widely used for lipidomics in
most laboratories, in which the detection parameters, such as
the number of precursor ions selected per cycle and dynamic
exclusion to minimize repeat precursor ions, can be optimized
to identify complex lipidmolecules [11]. DDAperformance, how-
ever, has several inherent limitations, such as limited dynamic
range, a bias toward high-abundance ions, and a long duty cy-
cle accompanying increase in sample complexity. The strategy
of data-independent acquisition (DIA) has recently been devel-
oped to alleviate these limitations [12, 13]. By collecting all frag-
ment ions simultaneously without any preselection, DIA could
thus enable in-depth analysis for both qualification and quan-
tification of lipids with improved detection sensitivity and anal-
ysis reproducibility. However, the DIA method is not easily ap-
plicable in lipidomics as the annotation and false discovery rate
(FDR) evaluation of MS features in large complex lipid datasets
requiremore sophisticated software and an integrated reference
database [14].
Here, we conducted a global lipidomics analysis of 293 Chi-
nese individuals, including 114 T2D patients, 81 prediabetic
subjects, and 98 individuals with NGT, using DIA-based liquid
chromatography–tandemmass spectrometry (LC-MS/MS). Using
commercial and in-house software to analyze the highly com-
plex dataset, we demonstrate that Chinese T2D patients pos-
sessed significant lipid changes in plasma compared with predi-
abetic and NGT individuals. Further, we identified several lipid
features, including lysophosphatidylcholine (lysoPC) and acyl-
carnitine species, that are potential indicators for predicting di-
abetic risk.
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Data Description
To delineate global lipidomic profiles in Chinese prediabetic and
T2D diabetic patients, fasting blood samples together with the
corresponding clinical and phenotypic data were collected from
114 T2D patients, 81 prediabetic individuals, and 98NGT individ-
uals in Suzhou, Jiangsu Province, China (Additional file 1). Lipids
were extracted from individual plasma samples and then in-
jected on the Waters XEVO-G2XS-QTOF instrument in both pos-
itive and negative modes, with pooled extraction quality con-
trol (QC) samples at certain intervals (Additional file 2). The raw
datasets were subjected to nonlinear alignment and normaliza-
tion by the commercial software Progenesis QI 2.0 and further
analyzed by the in-house pipeline metaX [15] to generate lipid
profiles. Univariate and multivariate analyses were conducted
using R statistics software to identify and evaluate the signifi-
cant lipidomic features among the groups.
Analyses
The 3 phases of the integrated workflow for this study are il-
lustrated in Fig. 1: phase 1, collecting information of clinical
specimens and acquiring mass signals from LC-MS/MS; phase
2, extractingmetabolic features through the software of MS data
analysis; and phase 3, identifying lipid candidates in response to
the development of T2D.
Assessment of clinical characteristics and plasma
lipidomic features
The clinical information including physiological and biochem-
ical parameters of the individuals included in the cohort is
summarized in Table 1. The levels of FPG, 2-hour postpran-
dial glucose (2h-PG), glycated hemoglobin (HbA1c), fasting C-
peptide, and insulin resistance index (HOMA-IR) were signifi-
cantly higher in both T2D patients and prediabetic individuals
than in NGT individuals, with T2D patients exhibiting higher
values compared with prediabetic individuals (Dunn’s post hoc
test, P < 0.05). T2D patients had higher age, BMI, waist–hip ratio,
systolic blood pressure (SBP), triglyceride, total cholesterol (TC),
and low-density lipoprotein (LDL) levels than NGT individuals
(Dunn’s post hoc test, P < 0.05). Further, the proportion of peo-
ple taking calcium channel blockers (CCBs) for hypertensionwas
higher in T2D patients than in prediabetic and NGT individuals
(chi-square test, P < 0.05).
We assessed both coverage and reproducibility of the non-
targeted lipidomic data on our large sample cohorts. Using Pro-
genesis QI 2.0 and metaX, the untargeted lipidomic analysis
yielded 11 077 features, with an average coefficient of variation
(CV) of 14.8% in the positive ion mode (PIM) and 923 features
with an average CV of 14.7% in the negative ion mode (NIM) af-
ter strict quality control (Additional file 3). Of the features in PIM,
approximately 46.77% (5181/11 077) were matched to 1 or more
molecular species with characteristic compatible with lipids or
lipid-like compounds, whereas the corresponding distribution
inNIMwas 36.72% (339/923). Principal component analysis (PCA)
showed that all of the QC samples spiked at certain intervals
clustered together, verifying an acceptable reproducibility and
stability of the results (Additional file 4). Twelve positive and 9
negative datasets were considered outliers and were removed
(Additional file 4A and B).
The interactions between the clinical parameters (Additional
file 1) and the global lipid profiles, obtained by combining
datasets from both ion modes (Additional file 3), were further
Figure 1: Flowchart for participant recruitment and data processing. The recruitment of participants was based on the 2011 World Health Organization criteria for
diabetes and prediabetes diagnoses. Blood and clinical data were acquired from 293 qualifying subjects, and untargeted lipidomics liquid chromatography–tandem
mass spectrometry analysis was performed. The raw data were preprocessed with Progenesis QI 2.0 to extract metabolic features. Unqualified variables and samples
were detected and discarded using the BGI in-house programmetaX [15]. Several types of statistical analyses such as rank sum tests, fold change analysis, partial least
squares discriminant analysis, and random forest analysis were performed to identify metabolites that differed significantly between the diagnostic groups. The lipid
compounds selected by the RF classifiers were identified by matching their accurate masses and mass spectrometryE ion spectral fragmentation patterns to those in
the database. Data-dependent acquisition analysis was applied to improve the resolving power for identification. See the Methods for more details.
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Table 1: Baseline characteristics in 3 groups of the study.
T2D Pre-DM∗ NGT T2D vs T2D vs Pre-DM
Variables (n = 114) (n = 81) (n = 98) P-valuea Pre-DMc NGTc vs NGTc
Gender (female), no. (%) 68 (59.65) 40 (49.38) 66 (67.35) 0.0513
Smoking, no. (%) 18 (15.80) 24 (29.63) 17 (17.35) 0.068
Hypertension, no. (%) 52 (45.61) 38 (46.91) 21 (21.43) 0.0002
CCB use, no. (%) 29 (25.43) 20 (24.69) 12 (12.24) 0.0372
Alcohol drinking, no. (%) 12 (10.53) 19 (23.46) 12 (12.24) 0.0769
P-valueb
Age, year 65.11 ± 8.77 61.99 ± 8.48 59.11 ± 9.15 4.52E–06 0.0356 4.81E–06 0.026
BMI 25.25 ± 3.14 25.23 ± 3.13 24.23 ± 3.26 0.0425 0.9965 0.0569 0.0569
Waist–hip ratio 0.92 ± 0.06 0.91 ± 0.06 0.89 ± 0.06 0.0166 0.6237 0.0291 0.0846
FPG, mmol/l 7.87 ± 1.99 5.91 ± 0.62 5.34 ± 0.36 2.20E–16 1.47E–13 3.49E–37 4.30E–06
2h-PG, mmol/l 15.1 ± 3.76 8.21 ± 1.63 6.01 ± 1.01 2.20E–16 3.23E–13 6.41E–41 1.30E–08
HbA1c, % 7.51 ± 2.06 5.51 ± 0.54 5.04 ± 0.42 2.20E–16 4.87E–15 5.19E–38 1.64E–05
Insulin, ulU/ml 8.85 ± 3.51 8.27 ± 3.75 7.39 ± 2.93 0.0017 0.2406 0.0004 0.0263
C-peptide, ng/ml 2.31 ± 0.99 2.07 ± 0.85 1.75 ± 0.69 4.55E–05 0.1524 1.70E–05 0.0079
HOMA-IR 3.13 ± 1.57 2.17 ± 1.03 1.76 ± 0.74 2.20E–16 3.64E–07 1.80E–21 0.0001
SBP, mm Hg 136.57 ± 24.26 130.91 ± 15.73 123.28 ± 16.81 3.69E–08 0.0129 9.75E–09 0.0036
DBP, mm Hg 79.73 ± 12.21 80.37 ± 8.12 77.35 ± 9.33 0.0345 0.6724 0.0653 0.0653
TG, mmol/l 2.04 ± 1.55 1.92 ± 1.19 1.55 ± 0.91 0.0051 0.6202 0.0149 0.0131
CHO, mmol/l 5.43 ± 1.39 5.22 ± 1.18 5.17 ± 1.43 0.2418 0.2083 0.2083 0.9262
LDL, mmol/l 3.86 ± 3.36 3.17 ± 2.00 2.56 ± 1.21 0.0014 0.2047 0.0005 0.0386
HDL, mmol/l 1.16 ± 0.35 1.14 ± 0.37 1.23 ± 0.32 0.2891 0.2225 0.6406 0.2029
Leptin, ng/ml 5.09 ± 1.91 4.29 ± 2.12 4.56 ± 1.67 0.0066 0.0013 0.0281 0.2107
GAD-Ab, lU/ml 13.66 ± 14.61 14.05 ± 13.14 12.92±17.45 0.066 0.3562 0.3173 0.1236
HsCRP, mg/l 2.62 ± 2.41 2.17 ± 1.81 2.16 ± 1.84 0.4485 0.7873 0.7873 0.7873
Adiponectin, ng/ml 37.41 ± 13.53 37.91 ± 16.57 39.2 ± 13.18 0.5321 0.6446 0.5684 0.5684
Values are given as mean ± SD or number of individuals (%).
∗The prediabetes (Pre-DM) group consisted of 7 isolated impaired fasting glucose (iIFT), 35 isolated impaired glucose tolerance (iIGT), 24 combined IFG/IGT, and 15
raised HbA1c.
aP-value of chi-square test.
bP-value of Kruskal–Wallis test.
cP-value of Dunn’s post hoc test.
evaluated by permutational multivariate analysis of variance
(PERMANOVA). The lipidomic datasets were significantly asso-
ciated with several plasma indices such as triglyceride, high-
density lipoprotein, TC, leptin, C-peptide, and HOMA-IR index,
and with physiological conditions, such as gender, waist–hip ra-
tio, BMI, and age (FDR < 0.05) (Additional file 5). Weak interac-
tions were also observed between the global lipid profiles and
other clinical parameters such as levels of fasting insulin, FPG,
LDL, SBP, and CCB treatment (FDR > 0.05) (P < 0.05).
Prediabetes and T2D-related lipidomic features
Because of the observed effects of CCB on lipid profiles, we per-
formed a blocked Kruskal–Wallis (KW) test, using CCB treatment
as the blocking factor, followed by Dunn’s post hoc test for pair-
wise comparisons. As shown in Additional file 6, 1590 features
displayed significant differences between the 3 groups, includ-
ing 1395 features in PIM and 195 features in NIM (P < 0.05, KW
test). Of these, 790 potentially matched lipids or lipid-like com-
pounds, including lysolipids, phosphatidylcholines, carnitines,
diglyceride, triglyceride, and several free fatty acids (FFAs). As
depicted in Fig. 2, pairwise comparisons revealed that 1269 fea-
tures displayed significant differences between NGT individu-
als and T2D patients, whereas 785 and 578 features showed sig-
nificant differences between prediabetic individuals versus NGT
individuals and T2D patients, respectively (P < 0.05)(Additional
file 6). The low number of variables distinguishing prediabetes
and T2D suggested that changes in a large fraction of the lipid
Figure 2: Venn diagram of significant metabolites from the 3 pairwise compar-
isons. Venn diagramdepicting the number of significantmetabolic features from
3 pairwise comparisons (the direction of change was ignored, P < 0.05, Dunn’s
post hoc test).
features in prediabetes and T2D were shared, implying that
compared with NGT, lipid profiles characterizing prediabetes
and T2D are similar. Further, 117 features maintained signifi-
cance after controlling the FDR by Benjamini–Hochbergmultiple
testing correction (FDR < 0.05)(Additional file 6).
To quantify the differential features among the 3 groups, all
detected features were assessed using criteria of fold change
(FC) in mass intensity ≥1.2 or ≤0.8 and variable importance of
the projection (VIP) >1.0 estimated by partial least squares dis-
criminant analysis (PLS-DA). Of the 1590 differential features,
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27.80% were significantly different between T2D and NGT, rep-
resenting 229 and 213 features at higher and lower levels, re-
spectively (Additional file 6). Only 7.36% of the features differed
significantly between T2D patients and prediabetic individuals,
representing 58 features present in higher abundance and 59
features present in lower abundance in T2D patients compared
with prediabetic individuals; 42.79% (98/229) of the lipid features
detected at higher levels in T2D patients than inNGT individuals
overlapped with metabolites detected at higher levels in predia-
betic than in NGT individuals. However, only 18.31% (39/213) of
the features detected at lower levels in T2D patients compared
with NGT individuals overlapped with metabolites detected at
lower level in prediabetic comparedwithNGT individuals. These
findings suggest that the pattern of changes in the levels of a
subset ofmetabolites reflect a continuous progression fromNGT
to T2D via prediabetes.
T2D risk evaluation using random forest classifier
As the qualitative and quantitative analyses revealed signifi-
cant differences in the lipid levels between the 3 groups and
indicated a gradual change from NGT to T2D via prediabetes,
we investigated if the lipid profile could predict risk of further
T2D development. To evaluate this possibility, arandom forest
(RF) classifier was used. Samples for T2D and NGT groups were
randomly divided into 2 sets, with 70 T2D and 70 NGT as the
training set and the rest as the validation set. As illustrated in
Fig. 3A, a model containing 28 features was successfully gener-
ated. The model exhibited excellent performance on the train-
ing set, with an area under the receiver operating character-
istic (ROC) curve (AUC) of 90.23% (95% confidence interval [CI]
= 84.95–95.52%) (Fig. 3B) and a high validated performance of
AUC of 86.24% (95% CI = 76.05−96.43%) (Fig. 3C). The T2D risk
prediction model was further used to evaluate the performance
in relation to distinguishing prediabetes from T2D or NGT. As
depicted in Fig. 3D–E, T2D or NGT was basically different from
prediabetes, with an AUC of 71.77% (95% CI = 61.95−81.58%)
or of 68.08 (95% CI = 54.87−81.28%), respectively. Additionally,
the risk probability (RP) for each sample was estimated and in-
dicated a gradually increasing risk from NGT to prediabetes to
T2D. Interestingly, similar increasing trends of RP were observed
in subgroups of the prediabetic individuals. A low risk was esti-
mated in subjects with high HbA1c levels of 5.7–6.4%, a slightly
higher riskwas estimated in subjects with isolated impaired glu-
cose tolerance (iIGT), and a high risk was estimated in subjects
with combined impaired fasting glucose (IFG) and impaired glu-
cose tolerance (IGT) (Fig. 3F). Information on selected features,
such as retention times (RTs), parent mass-to-charge ratio (m/z),
matching compounds, and lipid categories are presented in Ad-
ditional file 7, and the relative intensity levels of the features
are shown in Additional file 8 (A–AB). The relative intensities
of all selected features in T2D patients were significantly dif-
ferent from the levels in NGT subjects (Dunn’s post hoc test,
P < 0.05). In prediabetic individuals, the relative intensities of
these features were intermediate between T2D and NGT, and
the abundance of only a fraction of the features was signifi-
cantly different when comparing prediabetes with T2D or NGT.
Together, these results indicate that the lipid profile is regulated
in a complex manner during development of prediabetes and
T2D.
n n n n n
95% Cl = 84.95% – 95.52%
95% Cl = 61.95% – 81.58%
95% Cl = 76.05% – 96.43%
Figure 3: Random forest classification based on untargeted lipidomic profiling. (A) Distribution of 5 trials of 10-fold cross-validation error in random forest classifiers.
The model was trained using relative intensity of the detected features from both positive ion mode and negative ion mode in the training set of normal glucose
tolerant and type 2 diabetes patients (n = 70 and 70). The black solid curve indicates the average of the 5 trials (dash lines). The pink line marks the number of selected
features in the optimal set. (B) Receiver operating characteristic curve and area under the ROC curve for the training set. (C–E) ROC and AUC for validation set with
NGT and T2D (n = 21 and 36), prediabetes and T2D (n = 76 and 36), and NGT and prediabetes (n = 21 and 76), respectively. (F) Box-and-whisker plot presents the risk
probability of developing T2D among the validated NGT (n = 21), subgroups of prediabetes including HbA1c5.7–6.4% (n = 15) to iIGT (n = 32) to combined IFG/IGT (n = 23),
and T2D (n = 36) according to the RF model.
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Statistical analysis to define the correlation of
T2D-related lipid compounds and diabetic parameters
To explore the association structure between the lipidomic fea-
tures and clinical diabetic parameters, we performed a general
linearmodel regression analysis. In total, 81.38% (1294/1590) dif-
ferential features were significantly correlated with at least 1
of the diabetes-related indices after adjustment for age, gender,
and BMI, as well as hypertension, hyperlipidemia, smoking, and
alcohol history. All RF-selected features passed the cutoff point
of P < 0.05, and 65.69% (850/1294) met an FDR < 0.05 including 27
RF selected features except m/z 1019.7063 (electrospray ioniza-
tion [ESI]+, RT = 1.81 min) (Additional file 9). Among these 27 RF
features, we observed stronger relationships between metabo-
lites and glycemic variables (FPG, 2h-PG, and HbA1c) than beta-
cell function indices (fasting insulin, C-peptide, and HOMA-IR),
and weaker associations with age or BMI after adjusting for di-
abetes status and other confounders (Fig. 4). For instance, m/z
203.0533 (ESI+, RT= 0.58min) showed the highest positive corre-
lations with glycemic variables (beta = 0.625, 0.588, and 0.466 for
HbA1c, FPG, and 2h-PG, respectively), whereas a relatively weak
negative correlationwith age (beta= –0.197)was observed (Addi-
tional file 9). No statistically significant relationship betweenm/z
203.0533 (ESI+, RT = 0.58 min) and fasting C-peptide or insulin
levels was found (Additional file 9). Further, we observed an in-
verse relationship between lysoPC (P-16:0) atm/z 480.3456 (ESI+,
RT = 1.46 min) and the 6 diabetes-related indices. The abun-
dance of lysoPC (P-16:0) correlated strongly with beta-cell func-
tions (Beta = –0.334, –0.308, and –0.282 for HOMA-IR, C-peptide,
and insulin, respectively) but did not correlate with age, gender,
or BMI. Conversely, triglyceride (62:9) atm/z 967.8174 (ESI+, RT =
7.97 min) was negatively correlated with both diabetes-related
indexes and BMI. Among the 1590 differential features, several
potential triglyceride species, including triglyceride (48:1) atm/z
832.7403 (ESI+, RT = 8.25 min), triglyceride (50:1) atm/z 855.7427
(ESI+, RT = 8.46min), triglyceride (50:2) atm/z 853.7262 (ESI+, RT
= 8.35 min), and triglyceride (50:3) at m/z 851.7108 (ESI+, RT =
8.25 min), showed high positive correlations with both BMI and
C-peptide levels (P < 0.05) (Additional file 9).
T2D-related lipid identification using DDA
The RF-selected features were further identified by DDA and
classified by Metabolomics Standards Initiative (MSI) accord-
ing to their degree of physicochemical and/or spectral similar-
ity to available reference lipid standards or to published data
[16]. The m/z 248.1511 (ESI+, RT = 0.56 min) with a reported
prominent fragment ion at m/z 85 was annotated as hydroxy-
butyrylcarnitine (Additional file 10) [17]. The highest abundance
of this metabolite was detected in T2D, whereas the lowest lev-
els were found in NGT (Additional file 8C). By comparing mass
spectra of precursor ions using Progenesis QI 2.0, 2 RF-selected
negative features, namely m/z 508.3404 (RT = 1.7 min) and m/z
508.3406 (RT = 1.83 min), with different retention times but al-
most identicalm/z values, were both annotated as LysoPC (18:0).
The identity of the compound was subsequently confirmed by
comparison with the authentic reference standard, with the
most abundant peak at m/z 283.2641 corresponding to the acyl
anion fragments of stearic acid (Additional file 11). Further, m/z
506.3249 (ESI–, RT = 1.39 min) and m/z 504.3093 (ESI–, RT = 1.12
min) were annotated as LysoPC (18:1) and LysoPC (18:2), with
characteristic peaks at 281.2483 and 279.2326 as fragments of
oleic and linoleic acid, respectively (Additional files 12and 13).
We suggest that the peak with m/z 224 present in spectra of all
3 compounds is the product of ketene loss of the demethylated
lysoPCs (Additional files 11–13) [18, 19]. The levels of the 3 LysoPC
species were similar in NGT and prediabetes; however, the levels
of all 3 were significantly lower in T2D patients than in NGT and
prediabetic individuals (Additional file 8B, G, P, and R).
Figure 4: Heatmap of association between clinical parameters and 28 random forest-selected features. A hierarchically clustered heatmap of standardized regression
coefficient (beta) of genera linear model analysis showing the correlations between the relative abundances of the 28 significant metabolites and the phenotypes. Red
indicates positive correlations, and blue indicates negative correlations. The asterisk denotes a false discovery rate of <0.05 for each regression correlation. The cross
denotes a P-value <0.05 and an FDR > 0.05, and the space denotes a P-value ≥ 0.05.
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Discussion
Prediabetes, representing a high-risk condition that precedes
onset of T2D, has attracted significant attention in relation to
T2D prevention and pathogenesis research. To evaluate the risk
of T2D development, Morris et al. examined 70 follow-up stud-
ies where prediabetic subjects were defined by different criteria
and estimated the progression rates per 1000 person-years from
prediabetes to T2D. The meta-analysis demonstrated T2D inci-
dences of 35.54/1000 for HbA1c6.0–6.4%, 45.46/1000 for iIGT, and
70.36/1000 for combined IFG/IGT [20]. The T2D risk of similar
prediabetic subgroups in this study, HbA1c5.7–6.4%, iIGT, and com-
bined IFG/IGT, was assessed using the RF algorithm, which pre-
dicted a gradually increased T2D risk from HbA1c5.7–6.4% to iIGT
to combined IFG/IGT. This prediction is overall consistent with
the progression rates determined in the analysis of Morris et al.
[20], but we also emphasize that a thorough statistical valida-
tion using longitudinal studies ofa larger cohort will be required
to demonstrate the clinical utility of our model in the Han Chi-
nese population. The low risk probability predicted for predia-
betic individuals diagnosed with elevated HbA1c suggests that
appropriate HbA1c criteria for Chinese prediabetic individuals
should also be determined. Interestingly, Meikle’s group has de-
veloped several T2D risk classification models to evaluate their
performances in relation to stratifying T2D and IGT fromNGT, all
with FPG < 6.1 mmol/L. As reported, their combined model with
common risk factors and certain plasma lipids showed a maxi-
mum AUC of 0.826 and significant gains in both a mean AUC of
0.049 (P < 0.001) and a net reclassification improvement of 10.5%
(P < 0.001) compared with the model based solely on common
risk factors such as BMI, gender, and HbA1c [8]. Diglyceride and
triglyceride species are the 2 most frequently incorporated lipid
classes in the classification models, including the diglycerides
16:0/16:0, 16:0/22:5, and 16:0/22:6, and triglyceride 14:1/16:1/18:0.
As mentioned above, a significant number of lipids from these
2 classes showed significant differences between the3 clinical
groups in our study, though, with few species incorporated in
the risk predictionmodel. Our results, togetherwith results from
earlier studies, indicate that plasma lipid species might reflect
some of the more subtle pathological changes during diabetic
development.
In the present study, the major lipidomic alterations as-
sociated with T2D were characterized by enhanced levels
of acylcarnitines and decreased levels of lysophosphatidyl-
cholines. At MSI level 2, the abundance of hydroxybutyryl-
carnitine at m/z 248.1511 (ESI+, RT = 0.56 min) (Additional
file 8C) was found to increase from NGT to prediabetes to
T2D (KW test, P = 2.39E-9, FDR = 1.32E-5) (Additional file 6).
In vivo, D-3-hydroxybutyrylcarnitine can be converted to D-3-
hydroxybutyric acid, which is the predominant ketone body
found during diabetic ketoacidosis [21–23]. Notably at MSI level
4, the abundance of hydroxybutyric acid at m/z 103.0391 (ESI–,
RT = 0.61 min) (Additional file 8J) was also higher in T2D pa-
tients than in both prediabetic and NGT individuals (KW test, P
= 2.38E-8, FDR = 1.01E-5) (Additional file 6) in this study. These
2 features also showed high positive correlations with glycemic
variables and HOMA-IR (Fig. 4, Additional file 9). Increased D-3-
hydroxybutyric acid level has also been suggested as an early
biomarker of insulin resistance, which may be linked to mito-
chondrial dysfunction and the resultant oxidative stress [21].
Both T2D and prediabetes displayed relatively higher con-
centrations of several short- and long-chain AcylCNs, such as
L-acetylcarnitine (C2) at m/z 203.1160n (ESI+, RT = 0.57 min;
P = 6.66E-04, FDR = 0.066), tetradecanoylcarnitine (C14) at m/z
372.3115 (ESI+, RT = 0.99 min; P = 1.46E-03, FDR = 0.094), 2-
hydroxyhexadecanoylcarnitine (C16OH) at m/z 416.3371 (ESI+,
RT = 1.02 min; P = 1.60E-04, FDR = 0.044), and 12-hydroxy-
12-octadecanoylcarnitine (C18OH) at m/z 444.3667 (ESI+, RT =
1.38 min; P = 5.70E-04, FDR = 0.066) (KW test, Additional file 6).
As reported, accumulation of these incompletely oxidized lipid
species, likely derived from fatty acid or amino acidmetabolism,
may contribute to insulin resistance [6, 24]. Increased acylcar-
nitine concentrations in the plasma of patients with T2D and
prediabetes were also reported in the German population [25].
Lysophosphatidylcholine, an important signaling molecule
and fatty acid carrier, constitutes 5–20% of total plasma phos-
pholipids [26]. The alterations in species of LysoPC have been
widely studied in relation to diabetes and obesity. Significantly
lower levels of several LysoPC species in patients with IGT and
T2D, including LysoPC (18:2), LysoPC (18:1), LysoPC (18:0), and
LysoPC (17:0), were reported in a large cross-sectional study [27].
In addition, LysoPC (18:2) and glycine were selected and vali-
dated as strong baseline predictors for the risk of developing
IGT and/or T2D in a prospective analysis [27]. Finally, shotgun
lipidomics and data mining approaches revealed multiple in-
dependent associations between plasma lipidomic parameters
and insulin sensitivity indices, including a negative correlation
between LysoPC (22:5) and HOMA-IR [28]. It has been reported
that LysoPC species could enhance glucose-dependent insulin
secretion via G-protein-coupled receptor G119 both in vivo and
in vitro [29].
Comparing NGT and prediabetic individuals, we observed
a strongly significant reduction of lysophosphatidylcholine
species in the Chinese T2D patients including lysophosphatidyl-
choline (18:0) at m/z 508.3406 (ESI–, RT = 1.83 min; P = 3.01E–
7, FDR = 5.55E–05) and m/z 508.3404 (ESI–, RT = 1.7 min; P =
2.93E–05, FDR = 1.88E–03), lysophosphatidylcholine (18:1) at m/z
506.3249 (ESI–, RT = 1.39 min; P = 7.95E–06, FDR = 6.67E–04),
and lysophosphatidylcholine (18:2) at m/z 504.3093 (ESI–, RT =
1.12 min; P = 6.28E–06, FDR = 3.41E–03), which were selected
by the T2D prediction model (KW test, Additional file 6). Also,
lysophosphatidylcholine (22:5) at m/z 569.3440n (ESI+, RT = 1.01
min) showed a slight decrease in T2D and prediabetes (P = 0.027,
FDR = 0.310), while no significant associations with HOMA-IR
or other diabetes-related indices were observed. The differences
suggest the presence of distinct lipid profiles characterizing T2D
populations in China and Germany.
Some T2D-associated features are also tightly correlated
with obesity. Comparedwith lean control, Melissa et al. reported
a reduction of several LysoPC species in both obese T2D and
obese non-T2D subjects, while no differences were observed be-
tween the 2 obese groups [30]. In this study, 641 significant fea-
tures selected by the KW test displayed significant associations
with BMI, by adjusting age, gender, diabetes status, hypertension
history, hyperlipidemia history, smoking history, and alcohol
history, with 107 of them solely correlating with BMI (P < 0.05,
Additional file 9). Notably, 7 of the RF-selected features showed
additional significant associations with BMI, including the posi-
tively related PS (38:1) at m/z 800.5850 (ESI+, RT = 5.20 min) and
negatively associated LysoPC (18:1) at m/z 506.3249 (ESI–, RT =
1.39 min), TG (62:9) at m/z 967.8174 (ESI+, RT = 7.97 min), and
LysoPC (18:2) at m/z 504.3093 (ESI–, RT = 1.12 min) (Fig. 4, Ad-
ditional file 9). Lower levels of LysoPC (18:1) have also been ob-
served in obese subjects [31, 32]. In addition, a recent review
listing metabolic biomarkers of obesity and T2D noted a large
number of shared lipid biomarkers between the 2 disorders [33].
Additionally, 5 of the RF-selected features showed additional sig-
nificant negative associations with age, including m/z 203.0533
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(ESI+, RT= 0.58min) and LysoPC (18:2) atm/z 504.3093 (ESI–, RT=
1.12 min) (Fig. 4, Additional file 9). This indicates that there are
common alterations in lipid metabolism associated with T2D,
obesity, and aging, supporting the idea that greater BMI and ag-
ing are the 2 main risk factors for developing T2D [34–36].
We observed that CCB treatment (n = 61) for hypertension
showed slight effects on plasma lipid profiles (P= 0.0324 and FDR
= 0.0825) by PERMANOVA (Additional file 5), which was consis-
tent with an earlier report [37]. No significant effects were found
in relation to other medications, probably because of smaller
sample sizes or limited impacts (Additional file 5). Although fur-
ther validation is required to confirm and validate drug effects,
we suggest that the medications as possible interfering factors
on lipid metabolism [37, 38] should be carefully considered in
lipidomics-based investigations. Hence, we used strict statisti-
cal analyses to control for possible effects of treatment on T2D-
associated plasma lipids.
In summary, by using LC-MS/MS-based untargeted
lipidomics analysis, our study is the first large-scale study
to explore the alterations in the plasma lipid patterns of indi-
viduals with NGT, prediabetes, and T2D from East China. We
describe a large number of plasma lipids providing a broad
coverage of major lipid categories. We identify thousands of
plasma lipids exhibiting remarkable difference in abundance
between the 3 diagnostic groups, with a large proportion
displaying similar trends in prediabetes and T2D. Additionally,
we describe stratification of predicted diabetes risk between
subgroups of prediabetes based on 28 selected plasma lipids.
Several of the diabetes-related candidates have not previously
been reported. Together, this study provides a better biological
understanding of the insidious progression to diabetes from
a lipid perspective. More comprehensive studies combining
genomics, metabolomics, proteomics, and metagenomics
should be conducted to describe the detailed variations among
the prediabetes subgroups and to support precise prevention
and intervention steps for T2D.
Methods
Participant recruitment, sampling, and grouping
Four-hundred and thirty-three participants submitted written
informed consent forms andwere enrolled in the study from the
community health service centers of Suzhou Center for Disease
Prevention and Control (CDC). All participants underwent a 2-
step enrollment process. At the first visit, all participants were
subjected to physical examinations including height, weight,
blood pressure, and waist and hip circumference and completed
a face-to-face questionnaire on demographics, medication his-
tory, family health history, and other lifestyle factors via well-
trained local staff. The study enrolled only those participants
who met the following criteria based on questionnaire: 1) age
40 or older; 2) free of cardiovascular disease, severe renal dis-
ease, cancer, type 1 or monogenic diabetes, and other autoim-
mune diseases, as determined by self-reporting; and 3) no an-
tibiotic use during the past 2 months. Approximately 81.7% of
the participants in the cohort (354 out of 433) meeting the above
criteria were admitted to a blood screening test for diabetes
according to the 2011 WHO criteria [39]. The qualified partici-
pants without a self-reported history of T2Dwere given a 2-hour
75-g oral glucose tolerance test. Participantswith fasting or post-
prandial blood glucose levels above the diagnostic cut-off point
were asked to repeat the test on the next day. Blood medical
tests were performed by a Nanjing Kingmed Center for Clinical
Laboratory, which included FPG, insulin, C-peptide, HbA1c, lep-
tin, adiponectin, and blood lipid levels in addition to routine
blood tests. Fasting plasma was prepared within 1 hour after
blood withdrawal by centrifuged at 1600 g for 15 minutes. The
upper layers were carefully collected to avoid disturbing the
buffy coat cells. The isolated plasma samples were stored at
–80◦C and transported on dry ice to BGI-Shenzhen.
Finally, a total of 293 subjects were divided into the 3 diag-
nostic groups, namely the normal glucose tolerance group (n =
98), the prediabetes group (n = 81), and the T2D group (n = 114;
including 77 newly diagnosed and 37 self-reported patients). The
prediabetes samples were further classified into 4 subgroups: (i)
raised HbA1c 5.7–6.4% (defined by the WHO–HbA1c criteria only; n
= 15); (ii) isolated IFG (defined by an FPG level of 6.1–7.0 mmol/l
and a normal 2h-PG level; n = 7); (iii) isolated IGT (defined by a
normal FPG level and a 2h-PG level of 7.8–11.0 mmol/l; n = 35);
and (iv) combined IFG/IGT (defined by an FPG of 6.1–7.0 mmol/l
and a 2h-PG level of 7.8–11.0 mmol/l; n = 24). The study was ap-
proved by the Institutional Review Board of BGI-Shenzhen and
the ethical review committee of Suzhou CDC.
Lipidome data processing and analysis (Lipidomics)
Lipid preparation and extraction
The collected plasma samples were thawed on ice, and lipids
were extracted with isopropanol (IPA) using a previously de-
scribed method [40]. Briefly, 40 μL of plasma was extracted with
120 μL of precooled IPA, vortexed for 1 minute, and incubated
at room temperature for 10 minutes; the extractionmixture was
then stored overnight at –20◦C. After centrifugation at 4000 g for
20 minutes, the supernatants were transferred into new 96-well
plates and diluted to 1:10 with IPA/acetonitrile (ACN)/H2O (2:1:1,
v:v:v). The samples were stored at –80◦C prior to the LC-MS anal-
ysis. In addition, pooled plasma samples were also prepared by
combining 10 μL of each extraction mixture.
Ultra-performance liquid chromatography–mass spectrometry
method for lipidomics
Samples were analyzedwith an ACQUITYUPLC (Waters, Manch-
ester, NH, USA) connected to a XEVO-G2XS quadrupole time-of-
flight (QTOF) mass spectrometer (Waters) with ESI. The lipids
were separated using an Acquity UPLC charged surface hy-
brid C18 column (2.1 × 100 mm, 1.7 μm, Waters) with a
gradient mobile phase comprised of 10 mM ammonium for-
mate with 0.1% formic acid in acetonitrile/water (A, 60:40,
v/v) and 10 mM ammonium formate with 0.1% formic acid in
isopropanol/acetonitrile (B, 90:10, v/v). Before the large-scale
study, pilot experiments including 10-minute, 15-minute, and
20-minute elution periods were conducted to evaluate the po-
tential effects of mobile phase composition and flow rate on
lipids retention time. Both abundant lipid precursors ions and
fragments were separated in the same order with similar peak
shapes and ion intensities in PIM (Additional file 14A–C, Addi-
tional file 15A–C). Furthermore, the mixed QC samples with the
10-minute elution period also showed similar base peak inten-
sities of precursors and fragments with the test sample (Addi-
tional file 14D, Additional file 15D). Considering the large sam-
ple size of this study, we used an accelerated elution profile of 10
minutes, described in the following sections. The mobile phase
was delivered at a flow rate of 0.4 mL/min. The column was ini-
tially eluted with 40% B, followed by a linear gradient to 43% B
over 2 minutes, and then the percentage of B was increased to
50% within 0.1 minutes. Over the next 3.9 minutes, the gradi-
ent was further ramped to 54% B, and the amount of B was then
Downloaded from https://academic.oup.com/gigascience/article-abstract/6/7/1/3826996/Lipidomic-profiling-reveals-distinct-differences
by guest
on 29 September 2017
Lipidomic signatures of Chinese T2D 9
increased to 70% in 0.1 minutes. In the final part of the gradi-
ent, the amount of B was increased to 99% over 1.9 minutes. Fi-
nally, solution B was returned to 40% in 0.1 minutes, and the
column was equilibrated for 1.9 minutes before the next injec-
tion. The injection volume was 10 μL. Lipids were detected with
a XEVO-G2XS QTOF mass spectrometer in positive and negative
mode, which was operated in MSE mode fromm/z 50–2000, with
an acquisition time of 1 second per scan. The source tempera-
ture was set at 120◦C. The desolvation temperature and gas flow
were 600◦C and 800 L/h, respectively, and nitrogen was used as
the flow gas. The capillary and cone voltages were 2.0 kV(+)/
1.5 kV(–), and 30 V, respectively. Leucine encephalin (molecu-
lar weight = 555.62; 200 pg/μL in 1:1 acetonitrile:H2O) was used
as a lock mass for accurate mass measurements, and 0.5-mM
sodium formate solution was used for calibration. The samples
were randomly ordered, and 10 QC samples were initially in-
jected to condition the column. One QC samplewas injected and
analyzed every 10 samples to investigate the repeatability of the
data [41].
Acquisition of the high-quality non-targeted metabolic profile and
metabolite identification
The raw tandemmass spectrometry datasets were generated on
the Waters XEVO-G2XS QTOF instrument and processed using
commercial software Progenesis QI 2.0 (Nonlinear Dynamics,
Newcastle, UK), consisting of raw data import, selection of
possible adducts, peak set alignment, peak detection, decon-
volution, dataset filtering, noise reduction, compound identifi-
cation, and normalization with sum method. The analysis
parameters used were as follows: (i) possible adducts of [M+H]+,
[M+H–H2O]+, [M+Na]+, and [M+K]+ for ESI+ and [M–H]– for
ESI–; (ii) the retention time of 0.5–9 minutes; (iii) the peak width
of 1–30s; (iv) 10-ppm mass tolerance for the precursors; and (iv)
10-ppm fragment mass tolerance for theoretical fragmentation
searching to improve the confidence in compound identifi-
cation. The normalized peak data were further preprocessed
by an in-house software metaX [15]. The k-nearest neigh-
bor algorithm to further improve the data quality. PCA was
performed for outlier detection and batch effects evaluation
using the pre-processed dataset. Quality controlrobust spline
correction (QC-RSC) was fitted to the QC data with respect
to the order of injection to minimize signal intensity drift
over time. In addition, the relative standard deviations of the
metabolic features were calculated across all QC samples, and
those >30% were then removed. The high-resolution LC-MS/MS
features were identified using Progenesis QI 2.0 by search-
ing in the public databases including Human Metabolome
Database (HMDB) [42], LIPID MAPS Structure Database (LMSD)
[43], and LipidBlast [44] with the mentioned parameters. To
obtain reliable identification of the high-quality features,
matching lipids were filtered by defined retention time ranges
in terms of the application note of the CSHC18 UPLC System
provided by Waters Corporation [45]. RTs were 0.5–4 min-
utes for lysophospolipids including lysophosphatidylcholine,
lysophosphatidylethanolamine, lysophosphatidylglycerol,
lysophosphatidylserine, lysophosphatidic acid, and lysophos-
phatidylinositol species, 3–8.1 minutes for sphingolipids,
including sphingomyelin, ceramide and lactosylceramide, glu-
cosylceramide, and galactosylceramide species, 4–7.8 minutes
for phosphatidylcholine, phosphatidylethanolamine, phos-
phatidylglycerol, phosphatidylserine, phosphatidic acid, and
phosphatidylinositol species, 7.8–9.5 minutes for diglyceride,
triglyceride, and cholesteryl ester species in PIM (Additional file
14D, Additional file 15D), 0.5–4 minutes for lysophospolipids
and FFA species, and 4–9 minutes for phospholipids, in-
cluding phosphatidylcholine, phosphatidylethanolamine,
phosphatidylglycerol, phosphatidylserine, phosphatidic acid,
and phosphatidylinositol, and sphingolipid species in NIM. The
metabolites that could be matched to LMSD, LipidBlast, or the
aliphatic compounds of HMDB at the molecular framework
level were considered lipids and lipid-like features. DDA, which
covered the desired mass scan range of interest, was performed
to further aid in identifying the metabolites. Pure authen-
tic standard of lysophosphatidylcholine (18:0; product code:
855775P from Avanti Polar Lipids Inc, Alabaster, AL, USA) was
used to validate the lipids by comparing their MS/MS spectra
and retention time on theWaters XEVO-G2XS QTOF instrument.
The reported features were classified into MSI levels according
to the reported guidelines [16].
Data analysis
Univariate analysis: KW testing and fold-change
analysis
Blocked KW tests were conducted to detect differences in
metabolite concentrations among the 3 diagnostic groups af-
ter controlling for the potential confounding effects of CCBs.
The analysis was performed using the tools implemented in the
COIN software package (coin 1.1–2 in R 3.2.5). The P value was
adjusted for multiple tests using an FDR (Benjamini–Hochberg).
Dunn’s post hoc tests followed by pairwise comparisons were
performed: an equals sign indicates no significant difference,
and a greater than symbol indicates P-values < 0.05. Fold-
changeswere calculated by comparing themean concentrations
of each feature between groups.
To improve the performance of the subsequent multivariate
statistical analyses, all features were normalized to the range
of [0, 1] to stabilize the variance using a modified range-scaling
method with the following formula [46]:
x˜i j = xi j − ximin(ximax−ximin )
,
where x˜i j indicates the scaled value for ith variable (compound)
in the jth sample (which is valued by xi j ,) and ximax and ximin rep-
resent the maximum and minimum values for the ith variable
among the samples, respectively.
PERMANOVA for the influence of clinical and
lifestyle factors
PERMANOVAwas performed on the normalized lipid metabolite
profiles and phenotypes with Bray–Curtis distance (adonis func-
tion, vegan package in R 3.2.5). The number of permutations was
9999. The P-value was corrected for multiple tests using an FDR
(Benjamini–Hochberg) cut-off of 0.05.
PLS-DA analysis
Supervised PLS-DA was conducted through metaX [15] to dis-
criminate the different variables between groups. The VIP value
was calculated. A VIP cut-off value of 1.0 was used to select im-
portant features.
Random forest (ROC/AUC) analysis
The RF classifier (randomForest 4.6-12 in R 3.2.5) was trained on
140 randomly selected subjects (70NGT and 70 T2D) from the 273
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samples and then tested on the remaining subjects. All of the
features were supplied to the classifier. The analysis was con-
ducted with 5 repetitions of the 10-fold cross-validation, using
cross-validation error curves to selected features as described
by Feng et al. [47]. The risk probability of T2D for each subject
was computed by the selected features, and a ROC curve was
drawn, for which the AUC was calculated (pROC1.8 in R 3.2.5).
The selection frequencies of features were listed to measure the
importance of the variables, with a higher frequency indicating
the greater importance of a given metabolite for classifying T2D
andNGT. The RFmodel was further tested on the validation sets.
General linear model regression analysis
GLM regression analysis was conducted to investigate the asso-
ciations between metabolites and multiple clinical phenotypes.
In a model applied with metabolites and diabetes-related in-
dexes including FPG, 2h-PG, HbA1c, fasting insulin, C-peptide,
and HOMA-IR, the confounding factors including age, BMI,
gender, and CCB use were adjusted. The model applied with
metabolites and age was adjusted for diabetes status, BMI, gen-
der, and CCB use. The model applied with metabolites and BMI
was adjusted for diabetes status, age, gender, and CCB use. For
each feature, the standardized regression coefficient (beta) and
2-tailed P-value for the coefficient was calculated (glm in R 3.2.5).
A P-value of less than 0.05 was regarded as significant.
Additional files
Additional file 1: phenotypic and clinical information for 293 en-
rolled subjects.
Additional file 2: batch numbers and run orders for biological
samples and quality controls.
Additional file 3: detailed list of total detected plasma fea-
tures.
Additional file 4: principal component analysis of plasma
lipid profiling from biological samples and quality controls. Prin-
cipal component analysis was performed on all samples to iden-
tify run outliers and check for possible batch effects in both pos-
itive (A) and negative modes (B). The colors represent the differ-
ent sample classes: green for normal glucose tolerant, blue for
prediabetes, red for type 2 diabetes, orange for quality controls,
and black for outliers.
Additional file 5: permutational multivariate analysis of vari-
ance of the influence of clinical records or life habits on lipid
profile.
Additional file 6: detailed list of significant features among
3 groups.
Additional file 7: detailed list of 28 metabolic features se-
lected by random forest classifiers.
Additional file 8: box plot displays the relative intensity levels
of 28 selected diabetic-related features in normal glucose tol-
erance, prediabetes, and type 2 diabetes. The features are pre-
sented in order of decreasing importance according to the selec-
tion frequencies in a random forest model. One asterisk denotes
P < 0.05, 2 denote P < 0.01, and 3 denote P < 0.001 (Dunn’s post
hoc test).
Additional file 9: a generalized linear model analysis on 1590
significant features and clinical phenotypes.
Additional file 10: tandem mass spectrometry spectra of m/z
248.1511 (ESI+, RT = 0.56 min) and its inferred chemical struc-
ture. Product ion spectra obtained from MS/MS of m/z 248.1511
[M+H]+ in the positive ion mode. Each arrow indicates a pos-
sible site of fragmentation, including a product ion at m/z 85,
which could be produced by all acylcarnitine butyl esters, and
a product at m/z 103, which has been reported as aliphatic hy-
droxyl group-containing fragment to produce the ion at m/z 85.
These spectra indicate thatm/z 248.1511 corresponds to hydrox-
ybutyrylcarnitine +H. ESI+: positive electrospray ionization; RT:
retention times.
Additional file 11: extracted-ion chromatogram and tandem
mass spectrometry spectra of m/z 508.34 (RT = 1.70 minutes
and RT = 1.83 min) in quality control samples and lysophos-
phatidylcholine (18:0) standard reference. (A) and (C) display the
extracted-ion chromatogram of m/z 508.34 [M–CH3]– in quality
control sample and lysophosphatidylcholine (18:0) standard ac-
quired in the negative ion mode. (B) and (D) exhibit the tan-
dem mass spectrometry spectra of m/z 508.34 [M–CH3]– in the
QC sample and lysophosphatidylcholine (18:0) standard. Each
arrow in the MS/MS spectrum of lysophosphatidylcholine (18:0)
indicates a reported site of fragmentation, with the most in-
tense product ion at m/z 283.2639 corresponding to fatty acid
18:0. The other less abundant product ion atm/z 168 corresponds
to N-dimethylaminoethylphosphate anion, and ions at m/z 224
and m/z 242 to the products of ketene losses from demethy-
lated lysophosphatidylcholine (18:0). These spectra confirmed
the identification of m/z 508.34 (RT = 1.70 min, RT = 1.83 min)
as lysophosphatidylcholine (18:0)–CH3.
Additional file 12: tandem mass spectrometry spectra of m/z
506.3249 (ESI–, RT = 1.38 min) and its inferred chemical struc-
ture. Product ion spectra obtained from tandem mass spec-
trometry of m/z 506.3249 [M–CH3]– in the negative ion mode.
Each arrow indicates a possible site of fragmentation, with the
most intense product ion at m/z 281.2483 corresponding to 18:1
fatty acid. The spectra indicate that m/z 506.3249 corresponds
to lysophosphatidylcholine (18:1)–CH3.
Additional file 13: tandem mass spectrometry spectra of m/z
504.3093 (ESI–, RT = 1.12 min) and its inferred chemical struc-
ture. Product ion spectra obtained from tandemmass spectrom-
etry of m/z 504.3093 [M–CH3]– in the negative ion mode. Each
arrow indicates a possible site of fragmentation, with the most
intense product ion at m/z 279.2326 corresponding to 18:2 fatty
acid. These spectra indicate that m/z 504.3093 corresponds to
lysophosphatidylcholine (18:2)–CH3.
Additional file 14: the base peak intensity of precursors (MS1)
in positive ionmode across thewholemass range. (A–C) indicate
test plasma samples with liquid chromatography gradients of 20
minutes, 15minutes, and 10minutes. (D) indicates a quality con-
trol sample from this study with a retention time of 10 minutes.
As shown in (D), the common high abundant precursor ionsmay
represent characteristic patterns corresponding to certain lipid
species extracted from human plasma. For instance, the ions at
m/z 496.35 (RT = 1.31 min), m/z 524.38 (RT = 1.81 min), and m/z
758.58 (RT = 6.30 min) may be suggested as [lysophosphatidyl-
choline (16:0)+H]+, [lysophosphatidylcholine (18:0)+H]+, and
[lysophosphatidylcholine (16:0/18:2)+H]+, respectively [50], the
ions atm/z 780.56 (RT = 5.15 min) andm/z 782.57 (RT = 5.33 min)
as [lysophosphatidylcholine (36:5)+H]+ and [lysophosphatidyl-
choline (34:1)+Na]+, and ions at m/z 369.35 (RT = 8.47 min) as
[cholesterol–H2O+H]+, a cholestadiene cation generated from
cholesteryl esters [51]. The abundant ion at m/z 577.52 (RT =
8.42 min) has been reported to indicate the sodiated 18:2 fatty
acyl group containing a keto moiety formed by triglyceride
species [52].
Additional file 15: the base peak intensity of fragments
(MS2) in positive ion mode across the whole mass range. (A–C)
indicate test plasma samples with liquid chromatography
gradients of 20 minutes, 15 minutes, and 10 minutes.
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(D) indicates a quality control sample from this study with a
retention time of 10 minutes. The most abundant fragment ions
at m/z 184 have been reported as protonated-phosphocholine
moieties that are diagnostic for the phosphatidylcholine head
group class [53, 54].
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